Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities

NCT04991883 | Completed

• 1 other identifier: MFS
• Study Type: observational
• Target: 167
• Locations: 1 country
• Sites: 1

Brief Summary

Single institution case series review with a histological diagnosis of mixofibrosarcoma of the extremities from 01 Jan 1993 to 01 Dec 2017. The study will exam all the clinical, radiological, histological and immunohistochemical features of this tumour in all samples and in a limited serie of cases the presence of mutation of 50 genes cancer related.

Conditions

Sarcoma,Soft Tissue

Keywords

Mixofibrosarcoma

Outcome Measures

Primary Outcomes (2)

• disease-free survival

  identify patients with different risk classes in terms of disease-free survival (local and systemic recurrence).

  at baseline (Day0)

• overall survival

  identify patients with different risk classes in terms of overall survival.

  at baseline (Day0)

Interventions

case series review of clinical and histological data OTHER

We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with a diagnosis of Mixofibrosarcoma treated at the Rizzoli Institute from 1 January 1993 up to 01 December 2017

You may qualify if:

• Male and female patients treated at Rizzoli Institute from 01 Jan 1993 to 01 Dec 2017
• Diagnosis of mixofibrosarcoma of extremities
• Histological slides/formalin-fixed paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the histology analysis and molecular analysis
• Enough tumor biobanked material available for molecular analysis
• Presence of the biobank signed informed consent
• Written informed consent prior to any study-specific analysis and/or data collection

You may not qualify if:

• \) Patients with histological diagnosis different from mixofibrosarcoma of extremities

Sponsors & Collaborators

• Istituto Ortopedico Rizzoli: lead

Study Sites (1)

Istituto Ortopedico Rizzoli

Bologna, BO, 40136, Italy

Location

Related Publications (3)

• Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996 Apr;20(4):391-405. doi: 10.1097/00000478-199604000-00001.

  PMID: 8604805 RESULT

• Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010 Mar;251(3):506-11. doi: 10.1097/SLA.0b013e3181cf87fa.

  PMID: 20130465 RESULT

• Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamaguchi T, Hasegawa T, Yamashita T. MRI and histological evaluation of the infiltrative growth pattern of myxofibrosarcoma. Skeletal Radiol. 2008 Dec;37(12):1085-90. doi: 10.1007/s00256-008-0542-4. Epub 2008 Jul 16.

  PMID: 18629459 RESULT

MeSH Terms

Conditions

Sarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 20, 2021
• First Posted: August 5, 2021
• Study Start: September 1, 2021
• Primary Completion: December 1, 2022
• Study Completion: December 31, 2022
• Last Updated: May 19, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)